Colchicine is one of the oldest known drugs which has been used for over 2000 years as a remedy for acute gout flares. Given its anti-inflammatory and anti-viral properties, it is also being tested in COVID-19 patients. In a prospective, open-label RCT from Greece, 105 hospitalized patients were randomized to either standard of care (SOC) or colchicine plus SOC (Deftereos 2020). Participants who received colchicine had statistically “significantly improved time to clinical deterioration”. However, there were no significant differences in biomarkers and the observed difference was based on a narrow margin of clinical significance; according to the authors their observations “should be considered hypothesis generating” and “be interpreted with caution”. In a retrospective cohort there was some evidence on clinical benefit (Brunetti 2020).

Find the entire treatment chapter at



AcalabrutinibAnticomplement therapiesAzithromycinCamostatChloroquineColchicineConvalescent plasmaCorticosteroidsCytokine blockersFamotidineFavipiravirG-CSFHuman recombinant soluble ACE2HydroxychloroquineIbrutinibIloprostInterferonsJAK inhibitorsLeflunomideLopinavirMonoclonal antibodiesN-acetylcysteineOseltamivir(other) Protease inhibitors(other) RdRp inhibitorsREGN-COV2Umifenovir

Outlook | References

By Christian Hoffmann